Related Experiment Video
Updated: Jan 28, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Toxicities of CD19 CAR-T cell immunotherapy
Alexandre V Hirayama1, Cameron J Turtle1,2
1Clinical Research Division and Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract:
CD19-targeted chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy has demonstrated impressive results in B-cell malignancies, and CAR-T cell therapies targeting other antigens are in development for other cancers. Cytokine release syndrome (CRS) and neurotoxicity can be life-threatening in a subset of patients. The severity of CRS and neurotoxicity can be impacted by the disease burden, lymphodepletion regimen, and CAR-T cell dose. Tocilizumab and corticosteroids have been used to manage these toxicities, enabling CD19 CAR-T cells to be administered without obvious compromise in efficacy. Consensus criteria for grading and managing toxicities will facilitate the widespread application of this treatment modality.
Related Concept Videos
Tumor Immunotherapy
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Cell Specific Gene Expression
Batteries and Fuel Cells
What are Cells?
Basic Characteristics of Cells
A living cell has a plasma membrane, a bilayer of lipids that separates the aqueous solution inside the cell called the cytoplasm from the outside environment.
Furthermore, a living cell possesses genetic information...
What is Cell Signaling?

